ADAM19 and cardiac hypertrophy: Notably, overexpression of Adam19 did not abolish the left ventricle (LV) functional benefit of LIPUS (see Supplementary material online, Figure S10), and overexpression of Adam19 did not abolish the LV functional benefit of LIPUS on ventricular hypertrophy, fibrosis, cardiac function, and ventricular arrhythmia (VA) inducibility (see Supplementary material online, Figure S10A–F).